Catalysts for Takeda Pharmaceuticals USA Inc
143 tracked
Mar 31, 2026
approval
MESALAMINE — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 25, 2026
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 25, 2026
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 17, 2026
approval
ANAGRELIDE HYDROCHLORIDE — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 6, 2026
approval
ANAGRELIDE HYDROCHLORIDE — FDA approval
Takeda Pharmaceuticals USA Inc
→
Nov 21, 2025
approval
LIVTENCITY (MARIBAVIR) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Oct 10, 2025
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Sep 25, 2025
grant
UNIVERSITY OF TX MD ANDERSON CAN CTR — Project Title: Low-dose erlotinib and mesalamine for prevention of colitis-as...
Takeda Pharmaceuticals USA Inc
→
Sep 23, 2025
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Sep 23, 2025
approval
ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Sep 23, 2025
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Apr 18, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Apr 18, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Apr 18, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Apr 18, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Mar 22, 2024
approval
LIVTENCITY (MARIBAVIR) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Mar 19, 2024
approval
ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Mar 14, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Mar 14, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 23, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Feb 23, 2024
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Oct 13, 2023
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Oct 13, 2023
approval
ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Oct 13, 2023
approval
VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Sep 28, 2023
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Sep 27, 2023
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Apr 26, 2023
approval
LIVTENCITY (MARIBAVIR) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jan 25, 2023
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Sep 8, 2022
approval
LIVTENCITY (MARIBAVIR) — FDA approval
Takeda Pharmaceuticals USA Inc
→
Jun 17, 2022
approval
ENTYVIO (VEDOLIZUMAB) — FDA approval
Takeda Pharmaceuticals USA Inc
→